Hyperphosphatemia Treatment Global Market Rising Trends, Industry Size, Share Report, Growing Demand and Business Opportunities And Forecast 2024-2033 | Sanofi SA, Ardelyx Inc., Lupin Limited, Shire plc, Amgen Inc.

The hyperphosphatemia treatment market size has grown rapidly in recent years. It will grow from $4.1 billion in 2023 to $4.61 billion in 2024 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to increased incidence of chronic kidney disease (ckd), growth in aging population, high prevalence of diabetes and hypertension, expansion of dialysis patient population, advances in medical research and diagnosis of hyperphosphatemia.

The hyperphosphatemia treatment market size is expected to see rapid growth in the next few years. It will grow to $7.54 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to rise in lifestyle-related diseases contributing to hyperphosphatemia, continued growth in aging demographics, increasing awareness and diagnosis of hyperphosphatemia, expansion of emerging markets with high disease burden, higher prescription share of calcium-based phosphate binders in emerging countries. Major trends in the forecast period include advancements in hyperphosphatemia treatment technologies, integration of telehealth and remote patient monitoring, collaborations and partnerships for research and development, focus on patient education and lifestyle management in hyperphosphatemia, development of novel phosphate binders and therapies.

Market Overview -
Hyperphosphatemia treatment refers to a class of drugs that boost renal excretion to treat patients' hyperphosphatemia. The most efficient way to do this is through volume replenishment with saline and forced diuresis with a loop diuretic such as furosemide or bumetanide.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=5852&type=smp

Sustainable Growth Of Hyperphosphatemia Treatment Market Amid Rising Chronic Disease Prevalence
The increase chronic diseases among patients is driving the growth of the hyperphosphatemia treatment market. Chronic diseases are non-communicable and require long-term care. A vast majority of chronic diseases can be categorized as cardiovascular diseases, chronic kidney disease, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. Furthermore, in February 2023, according to SingleCare Services LLC, a US-based healthcare savings platform, the prevalence of kidney diseases is increasing and each year untreated kidney failure claims the lives of approximately 1 million individuals. There has been an increase in hyperphosphatemia among patients with end-stage renal disease (ESRD), thus contributing to an increase in demand for hyperphosphatemia treatment or drugs .

Competitive Landscape -
Major companies operating in the hyperphosphatemia treatment market report are Sanofi SA, Akebia Therapeutics Inc., AMAG Pharmaceuticals Inc., Ardelyx Inc., Astellas Pharma Inc., Fresenius Medical Care AG & Co. KGaA, Keryx Biopharmaceuticals Inc., Lupin Limited, Shire plc, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., Unicycive Therapeutics Inc., Vifor Pharma Management Ltd., Zeria Pharmaceutical Co. Ltd., Abbott Laboratories, Amgen Inc., AstraZeneca plc, B. Braun Melsungen AG, Baxter International Inc., Beckman Coulter Inc., Cleveland Clinic, DaVita Inc., Encompass Health Corporation, FMC Corporation, Hospital Corporation of America Healthcare Inc., Kyowa Kirin Pharmaceuticals Co. Ltd., Mayo Clinic, Medtronic plc, OPKO Health Inc., Roche Diagnostics Corporation, Siemens Healthineers AG, Sysmex Corporation, Tenet Healthcare Corporation, Thermo Fisher Scientific Inc., UnitedHealth Group Inc.

Rising Emphasis On Research And Development In Hyperphosphatemia Treatment Market
The increasing research and development activities are a key trend in the hyperphosphatemia treatment market. The company in hyperphosphatemia treatment are focused on research and development activities for the development of innovative therapies for the treatment of renal diseases and related chronic conditions. For instance, in May 2021, Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company, raised $60 million in a Series B round to accelerate its development activities of innovative drugs and solutions for the treatment of renal diseases, including hyperphosphatemia.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/hyperphosphatemia-treatment-global-market-report

Key Segments -
The hyperphosphatemia treatment market covered in this report is segmented -
1) By Product: Sevelamer, Calcium-Based Phosphate Binders, Iron-Based Phosphate Binders, Lanthanum Carbonate, Other products
2) By Distribution channel: Hospital Pharmacy, Retail Pharmacy, Online stores

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.